Data not all that great. It seemed Just better than nothing. But maybe FDA thinks nothing better.
I don't remember FDA saying data was good so file. I felt it was like…..it failed once, you treated 3000 peeps. File now or quit.
Maybe short if shorts cover first thing in morning and it pops to 37 or so. Sell at 37 then short. I don't think this gets approved now. Something isn't right. It failed once before.
OMG still…..I almost sold end of day. Darn it. Something didn't smell right. I still made a lot of money though. Cemp is my huge holding. Thank you Lord.
This isn't a far fetched scenario.
Where there is smoke……..fire. Something really stinks here. Im thinking FDA told them it may actually fail no matter how many more patients are dosed. It failed NDA already once before
Not me. Glad I had a nice profit.
Yea. I had nice profit. Just can't stay with a company that lies to me. It may work out for longs but its the price more than anything. Just too expensive for the hassle at 1500 x 1st yrs earnings.
If you guys haven't guessed……..this guy was probably hired to try to keep the pps down as that huge fund that bought in the last cple days wanted a good price. You would have to be a moron to short Cemp. But you never know….. just look at Acadia and all the amateur retail shorts over there getting their butts handed to them.
Yup. 70% resistant in Asia. It has already been discontinued in many hospitals around the world. It can mean death in many instances. There is a reason Cemp is trading at $35 . It isn't hype or a Pump and dump etc. Soli is the " real deal". Cheers
Love Cemp and Acad.
um….the key word from CC you are missing is" soon to be obsolete drug". Leaving Soli as the king of Macrolides!
TTPH is fairly priced. They will fetch the highest price ever for a hospital anti biotic in hospital but they have hit a " buy out" ceiling.I have concerns about the oral step down as well. I suggested to sell TTPH a week ago. Cemp…….is still undervalued. BIG TIME!
Azithromycin has been prescribed like candy for every minor infection in the book thus the high prescription rate. Cemp will attempt to be a good steward for Soli and limit Soli to its hard to treat indications. 10 billion will not happen in the first 4 yrs but once pediatrics are treated sales will soar. What will happen is that the doctors will start to prescribe Soli more and more for basic infections and as they want to know 100% that the patient gets healed. In the community setting where costs unfortunately are always the primary concern, and Soli being a safe but very powerful macrolide …….Soli will be the first drug off the shelf otherwise the patient relapses and ends up in the hospital where the bill for the insurer sky rockets. The average doctor actually has no idea what has attached a patients system most of the time and the cost conscience HMO'S etc will not spend money on lots of tests on a patient if Soli is there waiting to heal safely with slim chance of hospital visit. Don't forget Nash,COPD etc,…………Soli is a cash cow. Im thinking $120 share buyout if they buy now.